Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target?
In follow-up to a recently published randomized controlled clinical trial, Issa et al. provide evidence that systemic activity and physiological responsiveness of the renin aldosterone angiotensin system (RAAS) are well within normal limits in most kidney recipients during the first 5 years post-transplant. Implications of the results include the need to better understand intra-renal RAAS activity in transplanted kidneys and to identify patients in which the graft-protective effects of RAAS blockade are most relevant.
Department of Medicine, Division of Nephrology and Hypertension and The William J. von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota, USA.
Hatem
H
Amer
Regenerative Medicine Institute (REMEDI) and College of Medicine, Nursing and Health Sciences, National University of Ireland, Galway, Ireland.
Matthew D
MD
Griffin
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D012084:Renin-Angiotensin System / Q000187:drug effects*
D047228:Angiotensin II Type 1 Receptor Blockers; D019808:Losartan